Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02052427 · ClinicalTrials.gov registry record · Phase 2
Safety & Efficacy of Adipose-Derived Regenerative Cells in the Treatment of Chronic Myocardial Ischemia (ATHENA II)
A Phase 2 study, sponsored by Cytori Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT02052427: Completed Phase 2 study, sponsored by Cytori Therapeutics.
NCT02052427 is a Phase 2 study that has completed, run by Cytori Therapeutics. The registered enrollment target is 3 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02052427, a Phase 2 study, has completed, sponsored by Cytori Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
This is a prospective, randomized, placebo-controlled, double blind safety and efficacy clinical trial.
Primary Outcome
Change in Minnesota Living with Heart Failure Questionnaire prior to treatment and at 6 months post treatment.
Interventions
- DEVICE Placebo
- DEVICE Celution System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2014-01 |
| Est. Completion | 2016-10 |
| Phase | Phase 2 |
What the finished NCT02052427 record still lists
NCT02052427 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02052427 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02052427 about?
NCT02052427 is a clinical study titled "Safety & Efficacy of Adipose-Derived Regenerative Cells in the Treatment of Chronic Myocardial Ischemia (ATHENA II)". This is a prospective, randomized, placebo-controlled, double blind safety and efficacy clinical trial.
What is the current status of trial NCT02052427?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2014-01. Estimated completion is 2016-10.
What interventions are being tested in trial NCT02052427?
The interventions under investigation include: Placebo (DEVICE), Celution System (DEVICE).
Who is sponsoring clinical trial NCT02052427?
This trial is sponsored by Cytori Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02052427's enrollment target sits among peer trials
3 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia